Labcorp

LH

Market cap $23.8B

AISight® Dx will support fully digital workflows and AI-enabled insights across Labcorp's network of anatomic pathology labs and hospital collaborations to improve efficiency, collaboration and patient care BURLINGTON, N.C., Feb. 23, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced an expanded collaboration with PathAI to deploy AISight® Dx1, an FDA-cleared digital pathology platform, across its national network of anatomic pathology labs and hospital collaborations.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Labcorp Holdings Inc. (LH) Q4 2025 Earnings Call Transcript

LH beats Q4 EPS estimates with 18% growth, but a revenue miss and cautious investor reaction push shares lower in pre-market trading.

While the top- and bottom-line numbers for Labcorp (LH) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Labcorp Holdings (LH) came out with quarterly earnings of $4.07 per share, beating the Zacks Consensus Estimate of $3.95 per share. This compares to earnings of $3.45 per share a year ago.

Laboratory services provider Labcorp forecast annual profit above Wall Street estimates on Tuesday, banking on robust demand for its diagnostic tests.

Company Provides 2026 Guidance Financial results from Operations versus 2024: Revenue: Q4 of $3.52 billion vs $3.33 billion; Full year of $13.95 billion vs $13.01 billion Diluted EPS: Q4 of $1.98 vs $1.70; Full year of $10.46 vs $8.84 Adjusted EPS: Q4 of $4.07 vs $3.45; Full year of $16.44 vs $14.57 Free Cash Flow: Q4 of $490.3 million vs. $665.1 million; Full year of $1.21 billion vs $1.10 billion Provided Full-Year 2026 Enterprise Revenue, Adjusted EPS and Free Cash Flow guidance: Revenue of $14.61 billion to $14.79 billion; midpoint growth of 5.4% Adjusted EPS of $17.55 to $18.25; midpoint growth of 8.9% Free Cash Flow of $1.24 billion to $1.36 billion; midpoint growth of 7.8% Expanded partnerships with health systems and regional/local laboratories by signing or closing 13 transactions in 2025 Advanced leadership in specialty testing, launching more than 130 innovative new tests in 2025, including in oncology, women's health, neurology and autoimmune Announced strategic investment to build a modern, state-of-the-art 500,000 square foot Central Laboratory facility to address growth in demand BURLINGTON, N.C.

Labcorp (LH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.